[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Third Affiliated hospital of Zhejiang Chinese Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":391},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,40,68,97,122,145,166,192,219,240,262,285,307,329,351,373],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100640808","study-on-the-optimal-waveform-patterns-of-electroacupuncture-targeted-intervention-for-bells-palsy-based-on-surface-electromyography-characteristics-100640808",false,"NCT07598175","Study on the Optimal Waveform Patterns of Electroacupuncture Targeted Intervention for Bell's Palsy Based on Surface Electromyography Characteristics","Inclusion Criteria for Bell's Palsy Subjects：\n\n* Meet the above Bell's palsy diagnostic criteria;\n* Age 18-65 years, either gender;\n* Disease course in recovery phase (21 days ≤ course ≤ 6 months) and not recovered (FNGS 2.0 score \\>4);\n* Voluntarily participate in this study and sign informed consent.\n\nInclusion Criteria for Healthy Subjects：\n\n* Do not meet the above Bell's palsy diagnostic criteria;\n* Age 18-65 years, either gender, matched to Bell's palsy subjects within 5 years for age and gender;\n* Normal facial nerve function, FNGS 2.0 score = 4;\n* Voluntarily participate in this study and sign informed consent.\n\nExclusion Criteria for Bell's Palsy Subjects：\n\n* Facial trauma, skin lesions, or other diseases that may cause facial paralysis symptoms;\n* Diagnosed with Ramsay Hunt syndrome (herpes zoster oticus);\n* Bilateral facial paralysis;\n* Previous history of facial paralysis;\n* Facial synkinesis, contracture, or spasm already present;\n* History of facial surgery;\n* Uncontrolled diabetes, hypertension, severe cardiac, hepatic, or renal disease, cognitive impairment, aphasia, or mental disorders;\n* Pacemaker use;\n* Pregnant or lactating patients.\n\nExclusion Criteria for Healthy Subjects：\n\n* Facial trauma, skin lesions, or other diseases that may affect facial muscle activity;\n* Previous history of facial paralysis;\n* History of facial surgery;\n* Uncontrolled diabetes, hypertension, severe cardiac, hepatic, or renal disease, cognitive impairment, aphasia, or mental disorders;\n* Pacemaker use;\n* Pregnant or lactating patients.",true,"ALL","18 Years","65 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical study is to find out whether different electronic acupuncture wave forms can effectively treat recovery-stage Bell's palsy in adults and evaluate their safety.\n\nThe main questions it aims to answer are:\n\n* Can targeted electronic acupuncture wave forms improve facial nerve function in patients with Bell's palsy?\n* What is the optimal electronic acupuncture waveform for different degrees of facial nerve injury?\n* What adverse events may occur during electronic acupuncture treatment? Researchers will compare low-frequency continuous wave electronic acupuncture and intermittent wave electronic acupuncture to determine which waveform works better for recovery-stage Bell's palsy.\n\nParticipants will:\n\n* Receive either low-frequency continuous wave electronic acupuncture or intermittent wave electronic acupuncture every other day for 4 weeks\n* Undergo surface sEMG and ENoG examinations at baseline, Week 2, and Week 4\n* Complete facial function assessments and safety evaluations at each clinic visit",[27],"Bell's Palsy","NOT_YET_RECRUITING","2026-05-19",{"date":31,"type":32},"2026-05-20","ACTUAL",{"date":34,"type":21},"2026-05-15",{"date":36,"type":21},"2028-11-20",{"name":38,"class":39},"The Third Affiliated hospital of Zhejiang Chinese Medical University","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100633121","efficacy-of-acupuncture-on-chronic-tinnitus-and-its-association-with-auditory-brainstem-response-measures-100633121","NCT07522567","Efficacy of Acupuncture on Chronic Tinnitus and Its Association With Auditory Brainstem Response Measures","Efficacy of Acupuncture on Chronic Tinnitus and Its Association With Auditory Brainstem Response Measures: A Study Protocol for a Matched Case-Control and Self-Controlled Trial","Inclusion Criteria:\n\n1. Aged between 18 and 60 years, inclusive, any sex;\n2. No previous chronic functional or organic diseases, no head injury;\n3. No history of any psychiatric or neurological family genetic disease;\n4. Signed a paper version of the informed consent form and volunteered to participate in this trial.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women, and those who have a request for childbearing within the last six months;\n2. History of head trauma;\n3. Presence of metallic implants in the body or any other contraindication to ABR testing;\n4. Current participation in any other interventional clinical trial.","60 Years",{"count":49,"type":21},72,[24],"The goal of this clinical trial is to learn if acupuncture works to treat chronic tinnitus in adults. It will also learn about the neurophysiological effects of acupuncture on auditory conduction pathway function. The main questions it aims to answer are:\n\nDoes acupuncture lower tinnitus-related disability and severity, as measured by the Tinnitus Handicap Inventory (THI) and Tinnitus Effects Questionnaire (TEQ)?\n\nWhat changes in auditory brainstem response (ABR) parameters-such as wave I amplitude and wave V latency-occur after acupuncture treatment, and do these changes correlate with clinical improvement?\n\nResearchers will compare ABR parameters and clinical outcomes between chronic tinnitus patients and age- and sex-matched healthy controls to characterize tinnitus-related abnormalities. Additionally, the study will evaluate changes within the patient group before and after a 10-session acupuncture course to assess treatment efficacy and explore its neurophysiological mechanisms.",[53,54,55],"Tinnitus","Acupuncture","Auditory Brainstem Response",[57,58,59],"tinnitus","acupuncture","auditory brainstem response","2026-04-04",{"date":62,"type":32},"2026-04-13",{"date":64,"type":21},"2026-12-31",{"date":66,"type":21},"2027-07-31",{"name":38,"class":39},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100631123","efficacy-evaluation-of-electroacupuncture-in-the-treatment-of-functional-dyspepsia-100631123","NCT07496580","Efficacy Evaluation of Electroacupuncture in the Treatment of Functional Dyspepsia","Efficacy Evaluation of Electroacupuncture in the Treatment of Functional Dyspepsia: A Multicenter Clinical Trial Study","Inclusion Criteria:\n\n* Participants who meet the Rome IV diagnostic criteria for functional dyspepsia (FD).\n* Age 18 to 80 years, male or female.\n* Chinese patients with a normal upper gastrointestinal endoscopy within the past 1 year, or judged by a gastroenterologist with more than 3 years of clinical experience to have no structural disease that explains the symptoms.\n* Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Functional dyspepsia symptoms caused by severe or malignant diseases (e.g., liver cirrhosis, heart failure, or gastrointestinal tumors).\n* Helicobacter pylori infection, defined as a positive urea breath test or positive Hp test on endoscopy.\n* History of gastrointestinal surgery (except minimally invasive procedures such as laparoscopy).\n* Presence of a permanent or temporary cardiac pacemaker or use of external\u002Ftemporary pacing support.\n* Use of medications that may affect dyspepsia symptoms within 2 weeks prior to enrollment, including antisecretory drugs, antacids, prokinetic agents, digestive enzymes, nonsteroidal anti-inflammatory drugs, antidepressants, or traditional Chinese medicine for FD.\n* Conditions that may make participation difficult, such as severe mental or physical illness, dementia, or illiteracy.\n* Severe coagulation disorders.\n* Acupuncture treatment for gastrointestinal diseases within the past 1 month.\n* Participation in another clinical trial within the past 2 months.\n* Drug abuse or alcohol abuse.\n* Pregnant or breastfeeding women.","80 Years",{"count":77,"type":21},105,[24],"Functional dyspepsia (FD) is a common disorder that causes stomach discomfort, such as fullness or pain after eating, without any visible structural disease. Acupuncture is often used to manage these symptoms. This study aims to evaluate the safety and effectiveness of electroacupuncture-a form of acupuncture that uses gentle electrical stimulation-for treating functional dyspepsia. Specifically, the trial will compare the benefits of applying electroacupuncture to points on the abdomen (local points) versus points on the arms and legs (distal points), alongside a control group receiving a sham (inactive) treatment. The goal is to determine the most effective acupuncture strategy for improving patients' digestive symptoms and overall quality of life.",[81,82],"Functional Dyspepsia","Electroacupuncture",[84,85,86,87],"functional dyspepsia","electroacupuncture","Local Acupoints","Distal Acupoints","2026-03-22",{"date":90,"type":32},"2026-03-27",{"date":92,"type":21},"2026-03-01",{"date":94,"type":21},"2027-12-31",{"name":38,"class":39},4,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":120,"locationsCount":121},"100472371","efficacy-on-walking-ability-of-electroacupuncture-therapy-in-elderly-patients-with-sarcopenia-100472371","NCT05431010","Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia","Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia：a Randomized Controlled Trial","Inclusion Criteria:\n\n1. 60 years ≤ age ≤ 95 years, male or female;\n2. Patients are able to walk and communicate independently, and can complete required rehabilitation training;\n3. Patients meet the diagnostic criteria proposed by the Asian Working Group for Sarcopenia(AWGS);\n4. Patients volunteer to participate in this study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Patients with serious primary diseases of heart, brain, liver, kidney and hematopoietic system;\n2. Patients with severe mental illness, cognitive impairment, and disorientation;\n3. Patients have trauma and unsuitable for sports;\n4. Patients with electronic devices or metal objects implanted in the body;\n5. Patients can't complete the required rehabilitation training;\n6. Patients cannot receive EA treatment due to any reasons\n7. Patients are participating in other drugs, acupuncture and massage trials.","95 Years",{"count":106,"type":21},120,[24],"Introduction: The efficacy of existing therapies for the treatment of sarcopenia is still not satisfactory. Therefore, this randomized controlled, assessor-blinded study was designed to investigate the efficacy and safety of electroacupuncture(EA) therapy in elderly patients with sarcopenia.\n\nMethods and analysis: This randomized controlled trial will enroll 120 elderly patients with sarcopenia. Subjects will be randomly assigned in a 1:1 ratio to either EA combined with rehabilitation training group or rehabilitation training group through a central computerized randomization system. Primary outcome measure is lower limb mobility, including 6-minute walk test、timed get up and go test, and short physical performance battery. Secondary outcome measures include lower limb muscle mass and lower limb muscle strength. Outcome assessment will be conducted before the intervention, at 12 weeks after the intervention and at the end of the 12-week follow-up. Adverse reactions will be evaluated during the trial.\n\nConclusion: This research will provide evidence to clarify whether EA is effective and safe in the treatment of sarcopenia.",[110],"Sarcopenia",[112],"sarcopenia；electroacupuncture; geriatric","RECRUITING","2026-02-22",{"date":116,"type":32},"2026-02-24",{"date":118,"type":32},"2022-07-02",{"date":64,"type":21},{"name":38,"class":39},1,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":121},"100617932","biomechanical-study-of-lever-positioning-manipulation-on-scoliosis-100617932","NCT07325045","Biomechanical Study of Lever Positioning Manipulation on Scoliosis","Biomechanical Parameter Quantification and Finite Element Simulation of Lever Positioning Manipulation in Patients With Thoracolumbar Scoliosis","Inclusion Criteria:\n\n1. Age between 10 and 45 years, stable vital signs, no severe diseases in other systems;\n2. Diagnosed with scoliosis via standard anterior-posterior and lateral spinal radiographs, with a Cobb angle of 10° \\\u003C θ \\\u003C= 45°, and no severe complications;\n3. No history of spinal surgery;\n4. Voluntarily willing to participate in this study as a subject to undergo LPM procedures, and signing the informed consent form by themselves or their guardian. Note: Only patients meeting all of the above four criteria can be included in this study.\n\nExclusion Criteria:\n\n1. Individuals with severe osteoporosis, spinal fractures, tumors, infections, or lesions within the spinal canal;\n2. Those with related complications, such as cardiopulmonary insufficiency (NYHA class \\>= II) or severe neurological disorders;\n3. Those with compression fractures or spinal cord injuries;\n4. Individuals with cognitive impairment or mental disorders who cannot cooperate with biomechanical testing;\n5. Those with a history of spinal surgery;\n6. Those with severe skin lesions or dermatological diseases at the operation site;\n7. Women who are menstruating, pregnant, planning pregnancy, or in the postpartum period;\n8. Those with other conditions that may reduce the likelihood of completing the procedure, such as a fear of manual therapy;\n9. Individuals with unclear surface markers, affecting motion capture accuracy (e.g., BMI \\>= 35 kg\u002Fm\\^2).","10 Years","45 Years",{"count":132,"type":21},30,[24],"Research background Scoliosis is a common three-dimensional spinal deformity, especially in adolescents. In severe cases, it can lead to thoracic deformation and cardiopulmonary dysfunction. At present, clinical treatment is mainly based on Cobb angle to take observation, brace or surgical intervention, but there are problems such as poor compliance and large trauma. As a non-invasive massage therapy, leverage positioning manipulation has shown orthopedic effects in clinical practice, but its biomechanical mechanism has not been systematically quantified, which restricts its standardization and promotion.\n\nPurpose of the study The purpose of this study is to quantify the mechanical and kinematic parameters of lever positioning manipulation in the treatment of scoliosis through biomechanical testing and finite element simulation technology, to construct an individualized finite element model, to analyze the stress and strain distribution of each structure of the spine under the intervention of manipulation, to reveal its biomechanical mechanism, and to provide scientific basis for the standardization of manipulation and the optimization of curative effect.\n\nResearch contents and methods The study is divided into two parts : In the first part, 30 patients with scoliosis were recruited. Through the integrated mechanical sensor and motion capture system, the mechanical parameters ( such as preload force, maximum pull force ) and kinematic parameters ( such as angle, angular velocity ) during the manipulation were recorded in real time. In the second part, based on the CT data of patients, the three-dimensional finite element model of T10-L2 segment was constructed by using Mimics, Geomagic, SolidWorks and ANSYS software to simulate the loading process of manipulation and analyze the stress and strain response of vertebral body, intervertebral disc and ligament complex under the action of manipulation.\n\nExpected results and significance This study will systematically quantify the biomechanical characteristics of lever positioning manipulation for the first time, and clarify its mechanism of action in the treatment of thoracolumbar scoliosis. Through the finite element simulation, the stress distribution is visualized, which provides data support for the precision and individualization of manipulation, promotes the transformation of massage manipulation from ' experience dependence ' to ' quantitative science ', and lays a theoretical foundation for the development of intelligent orthopedic equipment in the future.\n\nEthics and quality control The study has passed the ethical review, and all participants will sign the informed consent. The manipulation was performed by the same experienced physician, and the data collection and analysis process was strictly controlled to ensure that the results were true and reliable.",[136],"Scoliosis","2026-01-06",{"date":139,"type":32},"2026-01-08",{"date":141,"type":21},"2026-01-10",{"date":143,"type":21},"2028-12-31",{"name":38,"class":39},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":165,"locationsCount":121},"100616695","effect-of-patient-controlled-transcutaneous-electrical-acupoint-stimulation-on-quality-of-life-in-chronic-cancer-pain-100616695","NCT07308951","Effect of Patient-Controlled Transcutaneous Electrical Acupoint Stimulation on Quality of Life in Chronic Cancer Pain","Clinical Efficacy Evaluation of Patient-Controlled Transcutaneous Electrical Acupoint Stimulation in Improving the Quality of Life for Patients With Chronic Cancer Pain","Inclusion Criteria:\n\n* Age between 18 and 80 years, regardless of gender;\n* Diagnosis of primary or metastatic malignant tumor confirmed by histopathology and\u002For cytology, consistent with the American Cancer Society criteria for malignancy;\n* Presence of cancer-related pain, defined as an average Numeric Rating Scale (NRS) score ≥ 2 over the preceding week or current regular use of opioid analgesics;\n* Life expectancy ≥ 3 months;\n* Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score ≤ 2, stable vital signs, clear consciousness, intact pain perception, unimpaired communication, ability to cooperate with study procedures and complete assessments;\n* Provision of signed informed consent by the patient or their legal guardian after comprehensive explanation of the study;\n\nExclusion Criteria:\n\n* Pain not attributable to cancer;\n* Severe cardiopulmonary dysfunction or respiratory depression;\n* Implantation of cardiac pacemaker or metallic implants at stimulation sites;\n* Local skin lesions or conditions unsuitable for TEAS at the acupoint sites;\n* Severe psychiatric disorders or significant cognitive impairment;\n* Concurrent participation in other clinical trials that may interfere with the outcome evaluation of this study;\n* Previous history of transcutaneous electrical acupoint stimulation (TEAS) or transcutaneous electrical nerve stimulation (TENS);",{"count":153,"type":21},290,[24],"This study aims to objectively evaluate the effect of Patient-Controlled Transcutaneous Electrical Acupoint Stimulation (PC-TEAS) on improving the quality of life in patients with chronic cancer pain, thereby providing evidence-based medical support for its efficacy and offering practical basis for patients to achieve home-based auxiliary treatment based on their own needs. Furthermore, by observing and comparing changes in indicators such as pain-related scores, analgesic consumption, emotional scores, spontaneous bowel movements, and adverse events, this research will comprehensively assess the advantages of PC-TEAS in the management of chronic cancer pain and explore other potential benefits of this intervention for patients.",[157,158],"Quality of Life","Chronic Cancer Pain","2025-12-15",{"date":161,"type":32},"2025-12-30",{"date":163,"type":32},"2025-09-10",{"date":64,"type":21},{"name":38,"class":39},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":173,"enrollmentInfo":174,"targetDuration":176,"studyType":177,"phases":4,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":121},"100612186","correlation-study-of-atrophic-gastritis-and-dyspepsia-symptoms-100612186","NCT07250308","Correlation Study of Atrophic Gastritis and Dyspepsia Symptoms","A Prospective Observational Study on the Correlation Between Pathologically Confirmed Chronic Atrophic Gastritis and Functional Dyspepsia Symptoms","Inclusion Criteria:\n\n1. Age 18-75 years\n2. Recent gastroscopic examination (within 1 year) suggesting chronic atrophic gastritis\n3. Underwent standardized pathological examination (5-point gastric mucosa biopsy according to the \"Updated Sydney System\" including antrum, body, and angle)\n4. Signed informed consent\n\nExclusion Criteria:\n\n1. Gastric cancer or suspected malignant lesions\n2. Concomitant significant other gastrointestinal diseases (e.g., ulcer, Barrett's esophagus, etc.)\n3. Autoimmune gastritis\n4. Unable to complete questionnaire survey","75 Years",{"count":175,"type":21},315,"1 Day","OBSERVATIONAL","Background:\n\nDyspepsia is a common gastrointestinal complaint globally, affecting approximately 21.8% of the population. Among patients presenting with dyspeptic symptoms, over 80% are diagnosed with functional dyspepsia (FD), while approximately 16% are found to have chronic atrophic gastritis (CAG). CAG represents an important precancerous condition in the gastric cancer cascade, yet the relationship between pathologically confirmed CAG and dyspeptic symptoms remains poorly understood. The significant symptom overlap between CAG and FD creates diagnostic challenges in clinical practice.\n\nStudy Objectives:\n\nThe primary objective is to determine whether there are significant differences in the prevalence and severity of dyspeptic symptoms (including epigastric pain, burning sensation, early satiety, and postprandial fullness) between patients with pathologically confirmed CAG and those without CAG (non-CAG group) among individuals who present with endoscopic features suggestive of atrophic gastritis.\n\nSecondary objectives include: (1) analyzing the independent effects of various covariates (Helicobacter pylori infection, dietary habits, sleep quality, psychological factors) on dyspeptic symptoms; (2) developing a symptom-based predictive model for pathological CAG; and (3) conducting exploratory serum metabolomics analysis to identify potential biomarkers and metabolic pathways associated with FD symptoms.\n\nStudy Design:\n\nThis is a single-center, prospective, observational study conducted at the Third Affiliated Hospital of Zhejiang Chinese Medical University. The study will enroll approximately 258-315 adult patients (aged 18-75 years) who undergo endoscopy showing features suggestive of CAG within the past year. All participants will undergo standardized 5-point gastric mucosal biopsy according to the Updated Sydney System. Based on histopathological results, patients will be classified into pathological CAG group (presence of gastric mucosal atrophy) or non-CAG group (absence of atrophy). The study aims to recruit at least 80 pathologically confirmed non-CAG patients for comparison.\n\nStudy Procedures:\n\nAfter obtaining informed consent, all enrolled patients will complete a comprehensive assessment at baseline including: demographic information, medical history, endoscopy and pathology results, Gastrointestinal Symptom Scale (GOSS) questionnaire using a 7-point Likert scale, H. pylori infection status (serology), dietary habits assessment, Pittsburgh Sleep Quality Index (PSQI), Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), and perceived stress evaluation. A subset of participants will provide fasting blood samples for non-targeted metabolomics analysis using liquid chromatography-mass spectrometry (LC-MS) to identify metabolites related to amino acids, organic acids, lipids, and neurotransmitter precursors. This is a non-interventional study with all data and sample collection completed at enrollment without long-term follow-up.\n\nPrimary Outcome:\n\nThe primary outcome is the difference between pathological CAG and non-CAG groups in the prevalence and severity of dyspeptic symptoms, particularly cardinal FD symptoms (epigastric pain, burning, early satiety, postprandial fullness), assessed using the GOSS scale. A symptom score ≥4 on any cardinal symptom will define the presence of clinically significant FD symptoms.\n\nExpected Duration:\n\nThe study is expected to last 24 months, including preparation, patient recruitment with data collection, and final statistical analysis and reporting phases.\n\nSignificance:\n\nThis study will provide evidence-based insights into the relationship between pathologically confirmed CAG and dyspeptic symptoms, potentially improving symptom management strategies and patient counseling. The metabolomics component may reveal novel biomarkers and pathways underlying symptom generation, laying groundwork for future mechanistic studies and personalized therapeutic approaches. Results will inform clinical practice and serve as preliminary data for larger-scale investigations.",[81,180],"Chronic Atrophic Gastritis (CAG)",[182,183],"Serumomics","symptom","2025-11-24",{"date":186,"type":32},"2025-11-26",{"date":188,"type":32},"2025-10-01",{"date":190,"type":21},"2026-08-31",{"name":38,"class":39},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":121},"100578979","phase-2-evaluation-of-clinical-efficacy-and-safety-of-specific-mode-electroacupuncture-stimulation-for-paclitaxel-across-bbb-delivery-in-patients-with-postoperative-recurrence-of-malignant-glioma-a-single-arm-trial-100578979","NCT06818331","Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial","Inclusion criteria\n\n1. WHO grade IV glioma as defined in the \"Integrated Diagnosis and Treatment Guidelines for Glioma of the Chinese Anti-Cancer Association\" (V2.0\\_2025 (20250110)).\n2. Recurrence confirmed by cranial MRI after surgical resection.\n3. According to the Response Assessment in Neuro-Oncology Criteria, version 2.0 (RANO 2.0) standards, there is at least one measurable lesion.\n4. Age ≥ 18 years and ≤ 70 years, gender not limited.\n5. If dexamethasone is used due to the space-occupying effect, the stable daily dose within 7 days before enrollment should be \\\u003C 6 mg; if the dose of dexamethasone is being reduced, the average daily dose within 7 days before enrollment should be \\\u003C 6 mg. Patients receiving dexamethasone treatment for reasons other than the space-occupying effect can still be enrolled.\n6. Karnofsky Performance Status Score (KPS) ≥ 40 points or World Health Organization (WHO) Performance Status Score ≤ 3 points.\n7. Good bone marrow function, liver and kidney function (within 14 days before treatment): a. Hemoglobin ≥ 90.0 g\u002FL; b. White blood cells ≥ 3.0\\*10\\^9\u002FL; c. Absolute neutrophil count ≥ 1500\u002FµL (white blood cell count \\* neutrophil percentage); d. Platelets ≥ 100\\*10\\^9\u002Fµl; e. Total bilirubin (TbIL) ≤ 5.0 x ULN; f. Serum aspartate aminotransferase (SGOT) ≤ 3 x ULN and TbIL ≤ 3.0 x ULN; g. Creatinine ≤ 1.5 mg\u002FdL, estimated glomerular filtration rate ≥ 30 mL\u002Fmin to \\\u003C 90 mL\u002Fmin)\n8. Able to receive electroacupuncture treatment and have good compliance.\n9. Clear consciousness, pain perception and discrimination ability, and basic communication ability.\n10. Signed the informed consent form and voluntarily participated in this study.\n\nExclusion criteria\n\n1. Seizure attack, uncontrollable.\n2. Those who are currently participating in other clinical trials or have completed other clinical trials within less than one month.\n3. Those who have received treatment containing paclitaxel or similar drugs.\n4. Those who have a severe allergy to paclitaxel or similar substances.\n5. Pregnant or lactating women.\n6. Those with diseases affecting cognitive function such as congenital dementia, or alcoholics, drug addicts or those with abuse of psychotropic substances.\n7. Those with infected skin at the acupuncture site.\n8. Patients with metallic foreign bodies in their bodies.\n9. Those who cannot undergo cranial enhanced MRI examination.\n10. Other acute or chronic diseases, mental disorders or abnormal laboratory test values that may increase the risk associated with participating in the study or the administration of the study drug, or interfere with the interpretation of study results, and the investigator determines that the patient does not meet the eligibility criteria for participation in the study.\n11. Those who are undergoing other types of anti-tumor treatments simultaneously during the trial, such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.","70 Years",{"count":200,"type":21},20,[202],"PHASE2","Gliomas are the most common type of primary brain tumors, with the main treatment modalities including surgery, radiotherapy, and chemotherapy. However, gliomas are highly prone to recurrence, posing significant treatment challenges, especially for high-grade gliomas, which have a 5-year survival rate of only 5.5%. Paclitaxel (PTX) is a common chemotherapeutic agent, and its in vitro antitumor efficacy is 1400 times stronger than that of temozolomide (the first-line chemotherapy drug for gliomas). However, due to its large molecular weight (approximately 893 Da), it cannot cross the blood-brain barrier (BBB), preventing its use as a first-line treatment for gliomas. Preliminary research by our team has demonstrated that Specific Mode Electroacupuncture Stimulation (SMES) can open the BBB, increasing the concentration of PTX in tumor tissues, peritumoral tissues, and surrounding invasive tissues, thereby exerting antitumor effects. Therefore, this study aims to preliminarily observe the safety and efficacy of SMES combined with PTX in treating patients with postoperative recurrent high-grade gliomas.",[205],"Glioma",[207,208,209,210],"glioma","Specific Mode Electroacupuncture Stimulation","Paclitaxel","blood-brain barrier","2025-05-29",{"date":213,"type":32},"2025-06-04",{"date":215,"type":32},"2025-02-10",{"date":217,"type":21},"2028-02-24",{"name":38,"class":39},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":15,"sex":16,"minAge":226,"maxAge":47,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":239,"locationsCount":121},"100583176","a-biomechanical-study-of-the-lumbar-intervertebral-disc-by-lever-positioning-manipulation-100583176","NCT06872918","A Biomechanical Study of the Lumbar Intervertebral Disc by Lever Positioning Manipulation","Study on the Stress-Strain and Flow-Solid Coupling Effects on Lumbar Intervertebral Discs Under Transient Loading by Lever Positioning Manipulation with Different Triggering Modes","Inclusion Criteria:\n\nHealthy volunteers:\n\n1. Healthy subjects with no history of lumbar spine disease, aged 20 to 60.\n2. No obvious lumbar spine pain or previous diagnosis of lumbar spine-related disease.\n3. Willing to participate in the study and have signed an informed consent form.\n\nPatients:\n\n1. Aged 20 to 60 years.\n2. Diagnosed with L4-L5 lumbar disc herniation by CT or MRI.\n3. Stable vital signs, no serious systemic diseases, and no complications.\n4. Willing to accept manipulation as a test subject.\n\nExclusion Criteria:\n\n1. Lumbar vertebrae fracture or dislocation.\n2. Lumbar spine or lumbar soft tissue tumor, tuberculosis.\n3. Lumbar spine fusion, paravertebral bone bridges, or severe osteoporosis.\n4. History of lumbar spine surgery.\n5. History of serious lumbar trauma.\n6. Lumbar skin inflammation, skin breaks, or other skin conditions.\n7. Serious primary diseases of the cardiac, hepatic, renal, or hematopoietic systems; psychiatric patients.\n8. Extreme frailty or pregnancy.\n9. Participation in other manipulative therapies that may interfere with the study.\n10. Intolerable adverse reactions.","20 Years",{"count":228,"type":21},128,[24],"Purpose of Study:\n\nThe purpose of this clinical trial is the clinical efficacy of different trigger modes of lever positioning manipulation (LPM) for the treatment of lumbar disc herniation (LDH). At the same time, the investigators considered from the perspective of virtual simulation and applied 3D finite element technology combined with dynamic capture system and mechanical sensing system to comprehensively evaluate the characteristics of biomechanical effects of different triggering modes of LPM on LDH.\n\nThe main questions ansthe investigatorsred are:\n\n(1) To clarify what is the clinical effect of LPM in treating lumbar disc herniation?(2) Summarize the spatial motion laws and mechanical characteristics of the two triggering modes of LPM. Analyze the correlation betthe investigatorsen the LPM operation characteristics and the individual characteristics of LDH patients as the investigatorsll as the imaging parameters, and clarify the differences betthe investigatorsen the two LPM two trigger modes.(3) To analyze the stress-strain effects of the two LPM triggering modes on the L4\u002F5 intervertebral discs and related accessory structures in different zones, and to elaborate the optimal type of LPM triggering modes for the treatment of LDH from the biomechanical point of view.(4) Under the condition of porous elasticity of the intervertebral discs, the investigators will study the effects of transient load on the flow-solid coupling of the intervertebral discs with different degrees of degeneration at L4\u002F5 in the two triggering modes of the LPM, so as to reveal the mechanism of the LPM intervention in the intervertebral discs' degeneration.\n\nThe main research includes the following four aspects:\n\n(1) Clinical efficacy study and standardized data collection of LPM.This study plans to recruit 128 volunteers from the Third Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine will be recruited for the study. Sixty-four LDH patients and 64 healthy volunteers the investigatorsre planned to be included in this study. The LDH patients the investigatorsre divided into lever positioning manipulation group (group 1, n=32) sham manipulation group (group 2, n=32) using random number table method. In this group, unilateral wrenching mode was used for patients with paracentral LDH and bilateral wrenching mode was used for patients with central LDH. Manipulation was performed every two days, receiving a total of 6 sessions over 2 the investigatorseks. Healthy volunteers the investigatorsre similarly categorized into unilateral trigger mode group (group 3, n=32) bilateral trigger mode group (group 4, n=32) using random number table method. LPM treatments the investigatorsre administered every two days, receiving a total of 6 sessions over 2 the investigatorseks. Participants in both Group 1 and Group 2 the investigatorsre required to complete clinical questionnaire assessments, including the Visual Analog Scale (VAS) and the Japanese Orthopaedic Association (JOA) scoring system. During the LPM operation, the performer wore a mechanical sensing glove to collect the mechanical parameters of the maneuver, while a motion capture system was used to collect the kinematic parameters of the LPM, and the individual characteristics and imaging parameters of all the volunteers the investigatorsre collected, so as to analyze the correlation betthe investigatorsen the mechanical parameters, kinematic parameters, and the individual factors of the patients with LDH.(2) Virtual simulation model building and maneuver loading analysis.One standard volunteer was selected among 64 healthy volunteers, and the lumbar spine-pelvis imaging CT data the investigatorsre imported into Mimics software for geometric model extraction and preliminary processing. Geomagic and other software the investigatorsre utilized to construct the lumbar spine 3D finite element simulation model. And based on Abaqus CAE finite element simulation software, two kinds of wrenching mode maneuvers of LPM the investigatorsre simulated and loaded. The kinematic and mechanical parameters of the LPM the investigatorsre disassembled and loaded into each model to obtain the analytical models of manipulation in different trigger modes. The experimental results the investigatorsre obtained by calculating and analyzing the working conditions of LPM through Abaqus software. Observe the stress and strain on the intervertebral disc and ancillary structures under the action of LPM in different pulling modes.(3) Fluid-solid coupling effect of LPM on lumbar intervertebral disc under transient loads.Under the condition of considering the porous elasticity of the intervertebral disc, the coupled flow-stress simulation in Abaqus CAE was utilized to study the coupled flow-solid effect of the intervertebral disc, and then loaded to simulate the LPM manipulation, and observed the changes such as the stress displacement of the intervertebral disc under the manipulation.",[232],"Lumbar Disc Herniation","2025-03-10",{"date":235,"type":32},"2025-03-12",{"date":237,"type":32},"2024-01-01",{"date":143,"type":21},{"name":38,"class":39},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":121},"100572767","phase-4-effect-of-specific-mode-electroacupuncture-stimulation-combined-with-ngf-on-dysphagia-after-ischaemic-stroke-a-pilot-randomized-controlled-trial-100572767","NCT06737549","Effect of Specific Mode Electroacupuncture Stimulation Combined with NGF on Dysphagia After Ischaemic Stroke: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients with first-ever ischemic stroke confirmed by Computed Tomography (CT) and\u002For Magnetic Resonance Imaging (MRI);\n2. Onset time ranged from 15 days to 180 days;\n3. Aged 18 to 80 years old, male or female;\n4. Dysphagia confirmed by a videofluoroscopic swallowing study (VFSS);\n5. Patients who are able to accept and comply with acupuncture, electroacupuncture treatment, gluteal intramuscular injection, and have good compliance;\n6. Have provided signed consent and exhibit willingness to participate in the trial.\n7. Women who are lactating, pregnant or intending to get pregnant;\n\nExclusion Criteria:\n\n1. Patients with dysphagia before ischemic stroke onset or dysphagia not caused by ischemic stroke;\n2. Patients with severe cognitive impairment;\n3. Patients with severe cardiac, hepatic, and renal dysfunction, as well as severe coagulation abnormalities;\n4. Patients with other abnormal test results who are deemed unsuitable to participate in this study by the investigator.\n5. Multiple occurrences of stroke, or a history of craniocerebral surgery, or cerebral infarction caused by trauma or brain tumors.\n6. Patients with severe neurological deficits prior to ischemic stroke, such as visual and auditory impairments, aphasia, agnosia, severe hemiplegia, and other conditions.\n7. Women who are lactating, pregnant or intending to get pregnant;\n8. Patients with a history of needle fainting or with skin infections at the acupuncture site.\n9. Cardiac pacemaker carrier;\n10. Patients allergic to NGF;\n11. The inability to undergo VFSS;\n12. Patients with a medication history that may alter cortical excitability within the past 2 months.\n13. Patients who are currently participating in other clinical trials or have participated in clinical trials that ended within the last 3 months.",{"count":247,"type":21},144,[249],"PHASE4","Ischemic stroke is a common clinical disease, often accompanied by dysphagia. At present, clinical treatment for patients with dysphagia after ischemic stroke is limited. The emergence of NGF has surprised the field of neurorehabilitation, but the clinical effect is not satisfactory. The main problem is that NGF is a macromolecular material with a molecular weight of 13.4 KD, which is difficult to penetrate the blood brain barrier. A large number of previous studies in our team have found that electroacupuncture with specific stimulation mode can open the blood brain barrier and induce NGF into the brain. Therefore, the purpose of this study is to investigate the effect of specific mode electroacupuncture stimulation combined with NGF treatment on patients with dysphagia after ischemic stroke and to explore the mechanism of this combination therapy to improve brain function, which creates a new method and theoretical basis for nerve rehabilitation of integrated traditional Chinese and Western medicine.",[252,253],"Ischemic Stroke","Dysphagia","2024-12-12",{"date":256,"type":32},"2024-12-17",{"date":258,"type":21},"2024-12",{"date":260,"type":21},"2027-12",{"name":38,"class":39},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":15,"sex":16,"minAge":226,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":22,"phases":271,"briefSummary":272,"conditions":273,"keywords":274,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":121},"100546978","peripheral-central-correlation-study-on-the-treatment-of-chronic-tinnitus-with-dao-qi-tong-luo-based-on-the-theory-of-connecting-the-two-ears-to-the-brain-100546978","NCT06401993","Peripheral-central Correlation Study on the Treatment of Chronic Tinnitus With \"Dao qi Tong Luo\" Based on the Theory of \"Connecting the Two Ears to the Brain\"","Inclusion Criteria:\n\n* Inclusion criteria for patients with chronic tinnitus\n\n  1. Chronic tinnitus patients, that is, the course of disease ≥6 months;\n  2. No contraindications of fNIRS scanning;\n  3. The age of 20 years ≤55 years old, gender is not limited, right-handed;\n  4. The external ear canal is unobstructed and the eardrum is intact\n  5. The average hearing threshold of both ears is \\\u003C35dB;\n  6. Normal expression and understanding ability. Inclusion criteria for healthy subjects\n\n  \u003C!-- -->\n\n  1. No tinnitus, no hearing disorders and other ear diseases;\n  2. Good health condition, no history of mental disease and nervous system disease;\n  3. No contraindications of fNIRS scanning;\n  4. The age of 20 years ≤55 years old, gender is not limited, right-handed;\n  5. The external ear canal is unobstructed, and the tympanic membrane is complete;\n  6. Normal expression and understanding ability.\n\nExclusion Criteria:\n\n* 1.A history of drug dependence or alcohol addiction; 2.Serious central system diseases or other systemic diseases such as cardiovascular and cerebrovascular diseases; 3. Patients with organic diseases such as craniocerebral trauma; 4. Sudden deafness, Meniere's disease, otosclerosis, acoustic neuroma and other inner ear or auditory nerve diseases; 5.External otitis, acute\u002Fchronic otitis media and other external ear middle-ear related diseases; 6. Patients with auditory hypersensitivity; 7. Pregnancy, preparation for pregnancy, breastfeeding population; 8. There are metal implants in the body, fNIRS detection contraindicated.","55 Years",{"count":270,"type":21},87,[24],"By comparing the clinical manifestations, ABR parameters and cerebral cortex blood oxygen levels of chronic tinnitus patients and healthy subjects under two different body states, the peripheral-central correlation of chronic tinnitus patients was explored, and the modern scientific significance of the theory of \"two ears connecting the brain\" was initially expounded. On this basis, the immediate and cumulative effects and peripheral-central correlation of \"dao qi tong luo\" intervention in chronic tinnitus were observed, and the effective mechanism of \"dao qi tong luo\" treatment was explored.",[53],[54,275,53,276],"Fnirs","ABR","2024-11-28",{"date":279,"type":32},"2024-12-03",{"date":281,"type":32},"2024-05-04",{"date":283,"type":21},"2026-12",{"name":38,"class":39},{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":198,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":298,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":121},"100460771","ea-for-bps-an-rct-and-study-for-central-mechanism-100460771","NCT05279963","EA for BPS: An RCT and Study for Central Mechanism","Electroacupuncture for Bladder Pain Syndrome: An Randomized Controlled Trial and Study for Central Mechanism","Inclusion Criteria:\n\n* 18 ≤ age ≤70 years, male or female;\n* Must fulfill the first and the second diagnostic criteria;\n* 30 mm≤ VAS score ≤80mm;\n* Participants can fully understand the study protocol and a written informed consent is signed.\n\nExclusion Criteria:\n\n* Patients with previous bladder stones or other space-occupying lesions;\n* Previous positive urine culture or significant abnormal urine routine;\n* Significant organic lesions of genitourinary system and pelvic organs;\n* Patients suffer from severe primary diseases such as cardiovascular, cerebrovascular, respiratory, liver and kidney, or patients cannot receive EA treatment due to any reasons;\n* People with heart stents and other metallic substances in their bodies;\n* Women who are pregnant, planning to become pregnant, breast-feeding or allergic to study drugs;\n* Patients have participated in other clinical trials within the last 3 months.",{"count":293,"type":21},84,[24],"This is a randomized controlled and assessor-blinded design trial to evaluate the efficacy and safety of acupuncture for bladder pain syndrome(BPS). All eligible participants will be randomly assigned to the medication group(n=21), EA group(n=42) and SA group(n=21) in a 1:2:1 allocation ratio. Participants will receive 4-week treatments phase followed by a 4-week follow-up phase. Outcomes will be assessed at baseline, during the treatment and at the end of the follow-up. Outcome assessors, data managers and statisticians will be blinded to the group allocation, while acupuncturists and participants will not be blinded for obvious reasons. Besides, fMRI will be used to collect spontaneous electrical activity of the brain of patients. In this trial, the investigators assume that electroacupuncture for BPS, compared to amitriptyline, is instrumental in improving symptoms such as pain, frequent micturition and emotional disorder.",[297],"Bladder Pain Syndrome",[85,299,300],"Randomized Controlled Trial","multi-modal magnetic resonance imaging",{"date":279,"type":32},{"date":303,"type":32},"2022-03-16",{"date":305,"type":21},"2025-01-23",{"name":38,"class":39},{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":198,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":121},"100503101","the-study-on-the-evaluation-of-acupuncture-therapy-on-primary-insomnia-100503101","NCT05830877","The Study on the Evaluation of Acupuncture Therapy on Primary Insomnia","The RCT Study on the Evaluation of Clinical Effect of Primary Insomnia Treated With the Tiaoshen Acupuncture","Inclusion Criteria:\n\n* Conforming to the diagnostic criteria of traditional Chinese and Western medicine for chronic insomnia;\n* Age range: 18-70 years old;\n* PSQI score\\>7 points; SAS score \\> 50 or SDS score \\> 53;\n* No communication and cognitive impairment;\n* No use or withdrawal of psychoactive drugs such as anti-anxiety within one month; ·No major physical diseases;\n* Those who voluntarily accept the research content and can complete various scale evaluations, polysomnography monitoring and HRV;\n* Sign an informed consent form prior to the start of the study.\n\nExclusion Criteria:\n\n* Those who do not meet the inclusion criteria;\n* Persons with a history of severe mental illness, severe head injury, and significant disturbance of consciousness;\n* Those with severe liver and renal insufficiency and bleeding tendencies;\n* Alcoholism (liquor ≥ 100ml\u002Fday), smoking (≥ 15 cigarettes\u002Fday), drug abuse or taking psychotropic drugs;\n* People with other sleep disorders, such as sleep apnea hypopnea syndrome, paroxysmal sleeping sickness, and REM sleep behavioral disorders;\n* Pregnant or nursing;\n* Those with other major diseases and poor control;\n* Other persons who are unwilling to sign informed consent.",{"count":293,"type":21},[24],"Through the recruition of outpatients who clinically meet the diagnostic criteria and inclusion criteria of PI, the acupuncture group adopts Tiaoshen acupuncture, and the placebo acupuncture group adopts non-insertive acupuncture supported by the Park device, and the Pittsburgh Sleep Quality Index (PSQI) is used as the main index to evaluate the patients through the scale; subjective indicators like Chalder 14-item fatigue scale, Epworth sleepiness rating, self-rating anxiety scale (SAS), self-rating depression scale (SDS) and objective indicators like polysomnography (PSG), heart rate variability (HRV) is regarded as a secondary index, and then evaluate the clinical efficacy of Tiaoshen acupuncture on PI and explore its mechanism.",[318],"Primary Insomnia",[58,318,320],"RCT","2024-06-13",{"date":323,"type":32},"2024-06-14",{"date":325,"type":32},"2023-05-10",{"date":327,"type":21},"2025-12-31",{"name":38,"class":39},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":335,"targetDuration":4,"studyType":22,"phases":337,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":350,"locationsCount":121},"100544114","application-of-machine-learning-based-on-fnirs-in-predicting-acupunctures-efficacy-in-treating-tinnitus-100544114","NCT06364670","Application of Machine Learning Based on fNIRS in Predicting Acupuncture's Efficacy in Treating Tinnitus","Inclusion Criteria:\n\n* Bilateral tinnitus that meets the diagnostic criteria for chronic subjective tinnitus.\n* Male and female, aged between 18 and 60 years.\n* Right-handed subjects who are able to comply with the study protocol and sign written informed consent.\n* Not participating in other clinical trials concurrently.\n\nExclusion Criteria:\n\n* Participants with objective tinnitus.\n* Participants have nervous system diseases or neuropsychiatric diseases that can significantly affect brain blood oxygen metabolism assessed by fNIRS.\n* Participants with severe cardiovascular and cerebrovascular diseases, malignant liver and kidney diseases, and other serious diseases.\n* Participants have any contraindications for acupuncture (such as a bleeding tendency).\n* Pregnant or lactating women.\n* Participants have received tinnitus treatment with drugs or other therapies in the last four weeks.",{"count":336,"type":21},500,[24],"This trial aims to use machine learning to analyze fNIRS imaging data of specific brain regions of tinnitus patients, thereby constructing a predictive model of the clinical efficacy of acupuncture for SNT.",[53],[58,341,57,342,343],"moxibustion","fNIRS","machine learning","2024-04-12",{"date":346,"type":32},"2024-04-15",{"date":348,"type":21},"2024-05",{"date":64,"type":21},{"name":38,"class":39},{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":198,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":360,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":372,"locationsCount":121},"100541474","phase-3-effect-of-electroacupuncture-combined-with-paclitaxel-clinical-efficacy-of-patients-with-recurrence-of-high-grade-glioma-100541474","NCT06330337","Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma","Specific Model Electroacupuncture Stimulation Promotes Paclitaxel Delivery Across the BBB for Postoperative Glioma Patients: A Randomized Controlled Study","Inclusion Criteria:\n\n1. Histologically confirmed high-grade glioma, with standard radiotherapy and chemotherapy post-surgical resection deemed unsuccessful, and recurrence confirmed by imaging.\n2. Age ≥18 and ≤70 years, open to all genders.\n3. If receiving dexamethasone for mass effect, a stable daily dose of \\\u003C6 mg in the 7 days prior to enrollment, or if the dose of dexamethasone is decreasing, an average daily dose of \\\u003C6 mg in the 7 days prior to enrollment. Patients receiving dexamethasone for reasons other than mass effect are still eligible.\n4. A Karnofsky Performance Score (KPS) ≥70 or a World Health Organization (WHO) performance status of ≤2.\n5. Meets the criteria for acupuncture, with no severe complications, able to undergo acupuncture treatment and demonstrates good compliance.\n6. Clear consciousness, with the ability to perceive and distinguish pain, and capable of basic communication.\n7. Signed informed consent, voluntarily participating in this study.\n\nExclusion Criteria:\n\n1. Uncontrolled epileptic seizures;\n2. Peripheral neuropathy \\> Grade 1;\n3. Currently participating in another clinical trial or having participated in a clinical trial that concluded less than 3 months ago;\n4. Previous treatment with paclitaxel or similar chemotherapeutic or biologic agents, or history of allergic reactions to these compounds;\n5. Patients with severe cardiac, hepatic, renal, or hematologic dysfunction (criteria within 14 days prior to treatment include: a. Hemoglobin ≥ 90.0 g\u002FL; b. White blood cells ≥ 3.010\\^9\u002FL; c. Absolute neutrophil count ≥ 1500\u002FµL; d. Platelets ≥ 10010\\^9\u002FµL; e. Total bilirubin (TbIL) ≤5.0 x ULN; f. Serum aspartate aminotransferase (SGOT) ≤10 x ULN and TbIL \\>3 to ≤5.0 x ULN; g. Creatinine ≤1.5 mg\u002FdL, estimated creatinine clearance ≥ 30 mL\u002Fmin to \\\u003C90 mL\u002Fmin);\n6. Pregnant or breastfeeding women;\n7. Individuals with cognitive impairments such as congenital dementia, or with histories of alcohol, drug, or psychotropic substance abuse;\n8. Individuals with a history of needle fainting or infections at the site of acupuncture;\n9. Patients with conductive foreign bodies within the body;\n10. Individuals unable to undergo enhanced MRI examinations.",{"count":359,"type":21},58,[361],"PHASE3","Gliomas are the most common type of primary brain tumors, with surgery followed by radiotherapy and chemotherapy as the main treatment modalities. However, they are highly prone to recurrence, presenting significant treatment challenges, especially for high-grade gliomas, which have a 5-year survival rate of only 5.5%. Paclitaxel, a common chemotherapeutic agent, exhibits antitumor effects in vitro that are 1400 times stronger than those of temozolomide (the first-line chemotherapy drug for gliomas). However, due to its large molecular weight (approximately 893 Da), it cannot cross the blood-brain barrier, precluding its use as a first-line treatment for gliomas. Preliminary research by our team has demonstrated that Specific Mode Electroacupuncture Stimulation (SMES) can open the blood-brain barrier, enhancing the concentration of albumin-bound paclitaxel (ABX) in tumor tissues, peritumoral tissues, and surrounding invasive tissues, thereby exerting antitumor effects. Consequently, this study aims to observe the safety and efficacy of SMES combined with ABX in treating patients with recurrent high-grade gliomas postoperatively, to explore its mechanisms of action, extend survival, improve quality of life, and forge new theories and methods for the integrative treatment of brain tumors combining traditional Chinese and Western medicine.",[205],[207,208,365,210],"protein-bound paclitaxel","2024-03-19",{"date":368,"type":32},"2024-03-26",{"date":370,"type":21},"2024-04-01",{"date":94,"type":21},{"name":38,"class":39},{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":121},"100530143","clinical-evaluation-of-surrounding-electroacupuncture-in-the-treatment-of-acute-lateral-ankle-sprain-100530143","NCT06182943","Clinical Evaluation of Surrounding Electroacupuncture in the Treatment of Acute Lateral Ankle Sprain","Inclusion Criteria:\n\n* Meets the diagnostic criteria for a grade I or II injury;\n* Onset time≤48h;\n* The patient aged between18 and 60, gender is not limited;\n* The skin of the ankle joint on the affected side is intact, without breakage or ulceration;\n\nExclusion Criteria:\n\n* Combined with ankle fracture;\n* Grade III injury or complete ligament rupture;\n* Those who cannot comply with the treatment program. Those with keloid, localized combination of other skin diseases, and those who are not suitable for electroacupuncture treatment;\n* Those with serious cardiovascular, cerebrovascular, hepatic, renal, hematopoietic system or systemic failure, connective tissue disease, hemophilia, diabetes mellitus, malignant tumors, and those who are prone to bleeding tendency.",{"count":293,"type":21},[24],"Comparison and evaluation of the difference in clinical efficacy of electroacupuncture combined with surrounding acupuncture and sham electroacupuncture groups and control group (ice compress combined with brake rest group) in the treatment of ALAS by means of musculoskeletal ultrasound technique.",[82],"2023-12-13",{"date":385,"type":32},"2023-12-27",{"date":387,"type":32},"2023-11-23",{"date":389,"type":21},"2026-11-22",{"name":38,"class":39},""]